Revenue
No reported data
Erasca, Inc. (ERAS)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $92.9M | $115.4M | $103.8M | $112.5M | $73.9M | $29.6M |
| Operating expenses | $140.9M | $179.6M | $141.5M | $247.4M | $124.9M | $109.3M |
| Operating income | −$140.9M | −$179.6M | −$141.5M | −$247.4M | −$124.9M | −$109.3M |
| EBITDAderived | −$137.8M | −$175.8M | −$137.8M | −$244.8M | −$124.1M | −$108.7M |
| Net income | −$124.5M | −$161.7M | −$125.0M | −$242.8M | −$122.8M | −$101.7M |
| Basic EPSper diluted share | -$0.44 | -$0.69 | -$0.83 | -$1.99 | -$1.85 | -$4.83 |
| Diluted EPSper diluted share | -$0.44 | -$0.69 | -$0.83 | -$1.99 | -$1.85 | -$4.83 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 1, 2026Form 4 · 10b5-1 | Garner EbunChief Legal Officer | SellCommon Stock | 80.0K | $16.40 | $1.31M | 25.1K |
| Mar 4, 2026Form 4 · 10b5-1 | Morris ShannonChief Medical Officer | SellCommon Stock | 20.0K | $15.04 | $300.8K | 0 |
| Jan 7, 2026Form 4 · 10b5-1 | Garner EbunGeneral Counsel & Corp. Sec. | SellCommon Stock | 120.0K | $5.59 | $670.8K | 25.1K |